INTRODUCTION
More than 400 species of microorganisms dwell in the human gastrointestinal tract. 1, 2 Balance between them is vital for the host's health. Present-day high usage of antibiotics, together with environmental and physiological factors, can alter this ecosystem. This imbalance can cause illnesses such as diarrhea, which was responsible for 1.31 million deaths in 2015, including 499,000 among children under five. 3, 4 Some research has shown that use of probiotics can confer some health benefits, such as treatment for diarrheal disease, prevention of systemic infections and other effects. 2, 5 The 2001 definition from the World Health Organization (WHO) states that probiotics are "live microorganisms which, when administered in adequate amounts, confer a health benefit on the host". 6 They are currently presented by media sources as an attractive health promotion method that prevents or cures a range of clinical situations. 7 Indeed, many trials assessing the effects of probiotics (including using different species of microorganisms) as preventive or therapeutic options for a range of diseases have been conducted and published. 2, 5 Consequently, a considerable amount of published data is currently available through MEDLINE. Corroborating this, a search in this database carried out on July 26, 2017, using the MeSH (medical subheading) term probiotics, retrieved 12,370 records, which corresponded to an increase of 278% in the number of records over the last ten years (from December 2007 to July 2017).
The questions that therefore arise are: Should probiotics be indicated for preventive purposes? And if so, for which patients? Which types of probiotics should be used, and at what dose and for how long?
In this review, we identified and summarized all Cochrane systematic reviews about the pre- 
OBJECTIVE
To summarize the evidence from Cochrane systematic reviews focusing on probiotics for prevention of any disease or condition.
METHODS

Design
Review of Cochrane systematic reviews.
Setting
Discipline of Evidence-Based Medicine of Escola Paulista de Medicina (EPM), Universidade Federal de São Paulo (UNIFESP).
Criteria for including reviews
• Types of studies
We only included the latest version of completed Cochrane systematic reviews (SR). We excluded any published protocols or any SR marked as "withdrawn" in the Cochrane Database of Systematic Reviews (CDSR).
• Types of participants
We included healthy participants or those diagnosed with any clinical condition or disease.
• Types of intervention This review included any probiotics that were used as preventive interventions and compared with no intervention, placebo or any other pharmacological or non-pharmacological intervention.
• Type of outcomes
We considered any clinical, social and laboratory outcomes, as evaluated in the systematic reviews that were included.
Search for reviews
We carried out a sensitive systematic search in the Cochrane Database of Systematic Reviews (via Wiley) on July 1, 2017.
The search strategy is presented in Table 1 .
Selection of systematic reviews
Two of the three researchers (VLB, LPDSR and DDB) independently and randomly selected and evaluated all references that were retrieved through the systematic search, to confirm their eligibility in accordance with the inclusion criteria. Any disagreements were resolved by consulting a more experienced author (RR).
Presentation of the results
We presented all the reviews included in this synthesis in a narrative manner (qualitative synthesis). The key points considered were their relevance, methods, results, quality of the body of the evidence for each outcome, and applicability.
RESULTS
Search results
The initial search resulted in 39 reviews and 13 protocols.
First, we excluded all protocols. After full-text assessment, we excluded 23 reviews since they either considered use of probiotics to be therapeutic interventions rather than preventive interventions or did not analyze probiotics alone. Thus, 16 Cochrane systematic reviews fulfilled our inclusion criteria and were summarized in this report.
Results from systematic reviews
Among the 16 systematic reviews included, a range of probiotic strains was used. Four systematic reviews tested their use only among adults, [8] [9] [10] [11] three only among children [12] [13] [14] and five among both adults and children, [15] [16] [17] [18] [19] while another four studies did not specify the age range of the population evaluated. [20] [21] [22] [23] Two systematic reviews addressed prevention of respiratory diseases, 11, 15 nine addressed prevention of gastroenterological diseases, 9, 10, 13, 14, [16] [17] [18] 20, 21 three addressed gynecological and obstetric diseases, 8, 22, 23 one addressed urological diseases 19 and one addressed immunological/allergic diseases. 12 A summary of the reviews included is presented below. The main findings for each comparison and the quality of the evidence (based on the GRADE approach) are presented in Table 2 .
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Very low to low quality of evidence
Acute upper respiratory tract infections
The review 15 
Bacterial sepsis and wound complications after liver transplantation
The review 16 
Infections after liver resection
The review 9 
Maintenance of remission in ulcerative colitis
The review 20 
Pouchitis after ileal pouch-anal anastomosis for ulcerative colitis
The review 10 assessed the effectiveness of different interventions for prevention of pouchitis after ileal pouch-anal anastomosis in cases of chronic ulcerative colitis. Thirteen RCTs were included in this review, but only two studies were about the use of probiotics. One RCT assessed prevention of pouchitis in patients with ileal pouch-anal anastomosis and showed that there were no benefits from using Bifidobacterium longum, in comparison with The authors concluded that, based on the few studies available, which were of small size (low quality of evidence), there was no benefit from using probiotics, in comparison with placebo or no treatment. For further details, and to check the probiotics used in each study, refer to the original abstract, available at: http://onlinelibrary.wiley.com/doi/10.1002/14651858.
CD008772.pub2/full.
Ventilator-associated pneumonia
The review 11 assessed the effects of probiotics for prevention of ventilator-associated pneumonia (VAP). Eight randomized clinical trials (RCTs) (1,083 adults) that compared use of probiotics with placebo, usual care and multiple treatment arms were included. Probiotics were shown to present some benefit regarding reduction of the incidence of VAP (odds ratio, OR 0.70; 95% CI 0.52 to 0.95; 8 RCTs; 1,018 participants; low quality evidence).
No difference was found between the probiotics and control groups in relation to the following outcomes,:
• intensive care unit (ICU) mortality (OR 0.84; 95% CI 0.58 to 1.22; 5 RCTs; 703 participants; very low quality of evidence);
• in-hospital mortality (OR 0.78; 95% CI 0.54 to 1.14; 4 RCTs; 524 participants; very low quality of evidence);
• incidence of diarrhea (OR 0.72; 95% CI 0.47 to 1.09; 4 RCTs; 618 participants; low quality of evidence);
• length of ICU stay (mean difference, MD -1.60; 95% CI -6.53 to 3.33; 4 RCTs; 396 participants; very low quality of evidence); 
Vulvovaginal candidiasis in HIV-infected women
The review 23 
Quality of evidence not assessed
Allergic disease and food hypersensitivity among children
The review 12 
Gestational diabetes in women without metabolic or chronic diseases
The review 8 evaluated the effects of probiotics for prevention of gestational diabetes mellitus (GDM). One RCT (256 pregnant women) was included and it found that there were benefits from use of probiotics (compared with placebo or diet) for reducing the rate of GDM (RR 0.38; 95% CI 0.20 to 0.70; 225 women) and for reducing the birthweight (MD -127.71 g; 95% CI -251.37 to -4.06; 256 women). No difference between the groups was found for the following outcomes:
• death (OR 2.00; 95% CI 0.35 to 11.35; 256 women);
• risk of premature birth (RR 3.27; 95% CI 0.44 to 24.43; 238 women);
• cesarean delivery (RR 1.23; 95% CI 0.65 to 2.32; 218 women).
All the infants included in this study were within the normal range for birthweight. The authors concluded that use of probiotics seemed to be associated with reduction in GDM. However, they considered that further studies would be required to confirm these results. For more details, and to check the form of probiotics used in each study, refer to the original abstract, available at:
http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD009951.
pub2/full.
Maintenance of remission of Crohn's disease
The review 18 The authors concluded that there was no evidence that probiotics were beneficial for maintenance of remission in cases of Crohn's disease. For further details, and to check the probiotics used in each study, refer to the original abstract, available at: http://onlinelibrary.
wiley.com/doi/10.1002/14651858.CD004826.pub2/full.
Necrotizing enterocolitis in premature newborns
The review 14 CD005496.pub4/full.
Postoperative recurrence of Crohn's disease
The objective of the review 21 
DISCUSSION
This overview found that despite increasing marketing of probiotics, there are still few systematic reviews on the preventive use of probiotics and there is a scarcity of high-quality randomized trials. None of the reviews included in the present study provided high-quality evidence for any outcome.
Many clinical trials assessed in this study showed very low or low quality of evidence. Another point that needs to be noted is the huge variety of probiotics that have been considered in RCTs.
This made it difficult to identify the individual effect of each probiotic agent, and also precluded meta-analyses.
Most of the studies focused on gastrointestinal diseases.
We found that there were some benefits from use of probiotics, with moderate quality of evidence, regarding their use for decreasing the incidence of antibiotic-associated diarrhea among children 13 and the incidence of Clostridium difficile-associated diarrhea among adults and children. 17 Other benefits that were observed with very low or low quality of evidence were that use of probiotics decreased the incidence of infections and the number of infectious episodes in patients undergoing liver transplantation. 16 The benefit of decreased incidence of severe necrotizing enterocolitis and mortality among preterm infants was noted in another review, but the quality of its evidence could not be assessed.
14 In relation to respiratory diseases, probiotics showed some benefits regarding decreased incidence of upper respiratory tract infections and duration of episodes, the need for antibiotics and missing school due to colds, 15 and regarding the incidence of ventilator-associated pneumonia in patients receiving mechanical ventilation. 11 These studies were classified as presenting very low or low quality of evidence, using the GRADE approach.
In three systematic reviews about gynecological and obstetric diseases, we found that there were some benefits in relation to decreasing the rate of gestational diabetes mellitus, decreasing both the birthweight 8 and the risk of vaginal infection, 22 although the quality of evidence could not be assessed. One RCT found that there was a benefit in relation to reducing the incidence of eczema among infants with a family history of allergy or food hypersensitivity and among healthy infants. 12 Despite the potential benefits of probiotics, we did not find any high-quality evidence that could change clinical practice or recommendations for their use. Furthermore, some probiotics may be harmful in groups of patients such as those presenting immunosuppression, severe debilitation and other such conditions. On the other hand, it is important to examine the number needed to treat
(NNT) and to analyze the cost-effectiveness of use of probiotics.
Goldenberg et al. concluded that the NNT to prevent one case of diarrhea was ten. Thus, in this example, probiotics reduced the number of cases of diarrhea even with only a few patients treated. 13 To prevent Clostridium difficile-associated diarrhea, 29 patients would need to be treated. 17 Our systematic review has the advantage of the number of studies included, given that the topic of probiotics is currently a matter of debate and that there are uncertainties regarding their effectiveness. Another advantage is that it summarizes the evidence relating to probiotics and their use that has been gathered in the Cochrane Library, which is recognized as the largest database of systematic reviews, given that the information about probiotics is distributed among many studies.
This overview has some limitations. Our search was conducted in a single database, even though the Cochrane Library is recognized as the most important database of systematic reviews. The limited data available is a consequence of the small number of papers, and the low quality of evidence is related to the small sample sizes and bias of the RCTs. Another point that should be noted is the huge variety of prebiotics that have been considered in RCTs, which led to difficulty in identifying the individual effect of each probiotic agent, and also precluded meta-analyses. The NNT was not determined in some reviews, which made it more challenging to analyze cost-effectiveness.
Regarding the implications for practice, our study summarizes the use of probiotics as a preventive intervention for some clinical settings and shows the situations in which there is a real benefit. From this, healthcare professionals can decide when to indicate probiotics for patients and can improve outcomes in their hospitals. For example, probiotics can be used to reduce the incidence of vaginal infection during pregnancy and to decrease the incidence of VAP. On the other hand, probiotics should not be recommended when there is uncertainty about their benefits and harm.
Here, we make it clear that much needs to be done in relation to studying probiotics. Firstly, basic research is needed in order to elucidate the pathophysiological links between different diseases and use of probiotics. Secondly, RCTs with high-quality evidence are needed, with larger sample sizes and better control over variables. Thirdly, research on the cost-effectiveness of use of probiotics needs to be stimulated, because their use must be analyzed in terms of their consequences for health and economic repercussions.
CONCLUSION
This overview included 16 Cochrane systematic reviews about the use of probiotics as preventive measures within clinical practice. There was little scientific evidence to support the use of probiotics. None of the reviews provided high-quality evidence for preventive action achieved through use of probiotics and each review analyzed only a few randomized controlled trials.
